CN102608051B - Reagent kit for diagnosis of leukemia - Google Patents
Reagent kit for diagnosis of leukemia Download PDFInfo
- Publication number
- CN102608051B CN102608051B CN201210041112.2A CN201210041112A CN102608051B CN 102608051 B CN102608051 B CN 102608051B CN 201210041112 A CN201210041112 A CN 201210041112A CN 102608051 B CN102608051 B CN 102608051B
- Authority
- CN
- China
- Prior art keywords
- kit
- damping fluid
- ring structure
- reagent
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention provides a reagent kit and a method for diagnosis of leukemia. Peripheral blood of a subject is taken as a testing object, bone marrow puncture is not needed to be performed, but accurate diagnostic results can be obtained. The trauma to a patient is small, the sensitivity is high, the specificity is high, the method only requires staining without washing, the operation is simple, the testing time is short, and the reagent kit and the method facilitate large-scale screening and follow-up treatment.
Description
Technical field
The invention belongs to field of medicaments, in particular to one for diagnosing leukemic kit.
Background technology
Leukaemia is the malignant tumour of hemopoietic system, cry again " leukemia ", in the incidence of disease of pediatric malignancies, occupy first, its mortality ratio arranges first place in the malignant tumour causing children and adult's death in less than 35 years old, is to threaten children and the modal malignant tumour of between twenty and fifty life and health.The leukemic incidence of disease of current China, occupies 6-8 position in various tumor incidence.
Leukemic pathogeny is the malfunction of hematopoietic tissue in the marrow formed due to the variation of DNA in cell.Stem cell in marrow can manufacture red blood cell and 7400/1 cubic millimeter white blood cell of about 5,400,000/1 cubic millimeter every day, and leukemia patient excessive production white blood cell and the leucocyte of majority is jejune, for juvenile cell, its survival period is longer than under normal circumstances.Although this quantity of leucocyte is very large, but can not be anti-infective as normal white cell.Thisly in body leukocyticly to increase, directly can affect the function of some vitals, affect the output of normal health haemocyte.Due to tumour cell neoplasm, suppress the generation of red blood cell and blood platelet hemostasis, even do not have enough normal white cell anti-infective, be easy to be scratched, hemorrhage, infect.And too much leucocyte also harms other work of marrow, this function making marrow produce other haemocyte reduces.
Leukaemia can be spread to lymph node, spleen, liver, central nervous system unify other organ, produces different symptoms.These symptoms, in main calcaneum marrow, the destruction of hematopoiesis function is relevant, as lasting fever, infects and prolongedly not to heal, anaemia, petechial hemorrhage etc.; Blood cell is also had to wear the symptom of oozing tissue and causing, as enlargement of lymph nodes, ostalgia or arthralgia, gum swelling, hepatosplenomegaly etc.
Leukemic diagnosis is very difficult, generally needs could finally make a definite diagnosis in conjunction with clinical manifestation, physical examination and laboratory assay three aspect comprehensive descision.White blood cell count(WBC) can reflect the risk of hemopoietic function of bone marrow exception to a certain extent, but only this inspection can not reach the needs made a definite diagnosis far away.Typically, make a definite diagnosis leukaemia, it is all necessary that periphery blood examination and bone marrow aspiration sampling detect.
But, due to bone marrow aspiration not easily by ordinary person is accepted, therefore clinical means that a kind of leukaemia Risk-warning cannot be provided at present, while also greatly hinder leukemic early detection and interventional therapy.When patient perceives, often enter the middle and later periods of leukaemia morbidity.In addition, the minimal residual of cancer cells in blood is an important indicator of prognosis, and for the accurate detection of minimal residual disease, to instructing, next step treatment of doctor is significant.But the sensitivity that current clinical conventional molecular biology for detection (PCR) can reach is only every 10
4individual haemocyte contains a cancer cell, limits the detection level to minimal residual disease.
Cyanine dyes is a kind of common dyes, has unique photaesthesia character, for centuries, is found, is used as developer gradually, photosensitizer, nonlinear optical material etc. with its unique physics and chemistry, optical property.
Summary of the invention
One aspect of the present invention provides a kind of for diagnosing leukemic kit.
Kit according to the present invention comprises reagent I and reagent II, wherein reagent I to be pH value be 6 ~ 8 damping fluid, reagent II is the compound shown in following formula I
Wherein: R
1for C
1-C
6alkyl, phenyl, alkyl replace phenyl; R
2, R
3, R
4and R
5independently selected from H or C
1-C
6alkyl, or R
2and R
3the ring structure of 5 yuan to 7 yuan is formed together with the carbon atom that they connect, or R
4and R
5the ring structure of 5 yuan to 7 yuan is formed together with the carbon atom that they connect; R
6and R
7independently selected from C
1-C
6alkyl; Y is halogen; X
1, X
2independently be selected from C, O, S, Se, Te.
According to kit of the present invention, wherein for the compound of formula I, its preparation method can with reference to Leslie G.S., Brooker and Frank L.W., JACS, 1935, the synthetic route recorded in 547-551, also can use additive method well known in the art to prepare.
According to kit of the present invention, wherein reagent I is preferably the damping fluid containing monovalent metallic ion of pH6 ~ 8, includes but not limited to sodium phosphate-phosphoric acid hydrogen sodium damping fluid, potassium phosphate-potassium hydrogen phosphate damping fluid, barbital sodium-hydrochloride buffer or citric acid-sodium citrate damping fluid.
According to kit of the present invention, wherein said C
1-C
6the alkyl of alkyl to be carbon number the be straight or branched of 1 to 6, include but not limited to, methyl, ethyl, n-pro-pyl, isopropyl, normal-butyl, isobutyl, the tert-butyl group, amyl group, isopentyl, n-hexyl or isohesyl etc.
According to kit of the present invention, wherein R1 is preferably methyl, ethyl, n-pro-pyl, isopropyl, normal-butyl, isobutyl, the tert-butyl group, amyl group, isopentyl, n-hexyl, isohesyl, phenyl, aminomethyl phenyl or 3,5-dimethylphenyl.
According to kit of the present invention, wherein R
2, R
3, R
4and R
5independently selected from methyl, ethyl, n-pro-pyl, isopropyl, normal-butyl, isobutyl, the tert-butyl group, amyl group, isopentyl, n-hexyl or isohesyl.
According to kit of the present invention, wherein R
2and R
3the carbon atom be connected with them can form the saturated rings structure of 5 yuan to 7 yuan or unsaturated ring structure, and described ring structure can contain or not contain N or S atom.
According to kit of the present invention, wherein R
4and R
5the carbon atom be connected with them can form the saturated rings structure of 5 yuan to 7 yuan or unsaturated ring structure, and described ring structure can contain or not contain N or S atom.
According to kit of the present invention, wherein Y is preferably fluorine, chlorine, bromine or iodine.
The leukemic method of another aspect of the present invention one diagnosis, said method comprising the steps of:
Extract the whole blood DNA of experimenter, the whole blood DNA of extraction is dissolved in reagent I and obtains DNA solution A;
By solution A at the temperature of 80 DEG C ~ 95 DEG C, preferably heat 2 to 15 minutes at the temperature of 85 DEG C ~ 95 DEG C, to make the DNA sex change in solution A, that is, double-stranded DNA depolymerization is made to be single stranded form, then, under making the temperature of solution A below 20 DEG C, at the temperature preferably below 10 DEG C, more preferably rapid quenching at the temperature of 4 DEG C, and under quenching temperature hold over night, obtain solution B;
Measure the most hyperfluorescenceZeng Yongminggaoyingguang intensity of the fluorescence emission peak of solution B within the scope of 570-580nm by fluorescence spectrophotometer, be designated as Fl
m 0;
Appropriate solution B is mixed to prepare solution C with appropriate reagent I and reagent II, and described reagent I and reagent II as defined hereinabove; Wherein the addition of solution B depends on the absorbance of solution C at 260nm place using uv-visible absorption spectroscopy instrument to measure, the absorbance of solution C at 260nm place is preferably in the scope of 0.01 to 1, in the scope of more preferably 0.1-0.3, the addition of reagent I and reagent II depends on the concentration of solution C compounds of formula I, and the compound concentration of solution C Chinese style I is 1uM to 100uM;
Measure the following index of solution C respectively:
The strongest absorbance of the absorption peak within the scope of 550-560nm, is designated as A
m;
The strongest absorbance of the absorption peak within the scope of 515-525nm, is designated as A
d;
The most hyperfluorescenceZeng Yongminggaoyingguang intensity of the fluorescence emission peak within the scope of 570-580nm, is designated as Fl
m;
The most hyperfluorescenceZeng Yongminggaoyingguang intensity of the fluorescence emission peak within the scope of 605-615nm, is designated as Fl
d;
According to above measurement result, calculate following index:
MD(A)＝A
M/A
D；
MD(Fl)＝Fl
M/Fl
D；
If MD (A) is less than 1.4, or MD (Fl) is less than 5.2, then can assert that experimenter suffers from leukaemia.
According to method of the present invention, wherein in the step of preparation solution C, solution B directly can be mixed with reagent I box reagent II and prepare solution C; Also first reagent II can be dissolved in reagent I, then the solution obtained is mixed with solution B prepare solution C.
Compared with prior art, provided by the invention for diagnosing the advantage of leukemic kit and using method and diagnostic system to be:
Detected object is the peripheral blood of experimenter, does not need to carry out bone marrow aspiration and can obtain diagnostic result accurately, not only little to patient trauma, and extensive examination of being more convenient for is treated with tracking;
High sensitivity, the employing supermolecule fluorescence probe of novelty, sensitivity is more than 100 times of traditional single molecule probe;
High specific, directly for the DNA extract in whole blood, leukemia diagnosis accuracy rate is about 85-97%;
Only need a step dyeing, without washing, simple to operate, detection time is short;
Instrument highly versatile, only needs to use routine clinical detecting instrument (uv-visible absorption spectroscopy instrument or fluorescence spectrophotometer);
Accompanying drawing explanation
Fig. 1 is the statistical graph of MD (A) index representing the experimenter obtained according to one embodiment of the invention;
Fig. 2 is the statistical graph of MD (FI) index representing the experimenter obtained according to one embodiment of the invention.
Embodiment
In more detail the present invention is described in the mode of specific embodiment below with reference to accompanying drawings, but be to be understood that, the present invention can implement in a different manner, these embodiments are provided to be only to make this instructions fully with complete, to enable those skilled in the art implement the present invention, the specific embodiment listed by scope of the present invention should not be defined as herein.
This tests all blood samples is all by Contract Research Organization (Contract Research Organization, CRO), obtains after signing formal clinical testing contract with hospital.The test of all blood samples is passed through discussion through Hospital Ethical Committee all.
Embodiment 1
Extract the whole blood DNA of 19 health volunteers and 33 leukaemics, be the PBS buffer solution of 6.0 respectively with pH by the whole blood DNA of extraction, obtain 52 parts of DNA solution A.
Every part of solution A is heated 15 minutes in the water-bath of 80 DEG C, then rapid quenching in the refrigerator of 4 DEG C, and in the refrigerator of 4 DEG C hold over night, obtain 52 parts of solution B.
The most hyperfluorescenceZeng Yongminggaoyingguang intensity Fl of the fluorescence emission peak of every part of solution B within the scope of 570-580nm is measured by fluorescence spectrophotometer
m 0.
The PBS damping fluid that to get appropriate solution B and appropriate pH be 6.0 is and compound
preparation solution C, make the prepared absorbance of 52 parts of solution C at 260nm place be 0.1-0.3, in solution C, the concentration of compound is 1uM.
Then the following index of each solution C is measured respectively:
The strongest absorbance of the absorption peak within the scope of 550-560nm, is designated as A
m;
The strongest absorbance of the absorption peak within the scope of 515-525nm, is designated as A
d;
The most hyperfluorescenceZeng Yongminggaoyingguang intensity of the fluorescence emission peak within the scope of 570-580nm, is designated as Fl
m;
The most hyperfluorescenceZeng Yongminggaoyingguang intensity of the fluorescence emission peak within the scope of 605-615nm, is designated as Fl
d;
According to above measurement result, calculate following index:
MD(A)＝A
M/A
D；
MD(Fl)＝Fl
M/Fl
D；
Carry out statistical study to MD (A) index of part solution C of 52 by obtaining with upper type, result as shown in Figure 1.Carry out statistical study respectively to MD (FI) index of 52 parts of solution C by obtaining with upper type, result as shown in Figure 2.
With reference to Fig. 1, can clearly be seen that (namely blood sample MD (A) index of 87.9% leukaemic is less than 1.4, accuracy rate of diagnosis is 87.9%), only blood sample MD (A) index of 10.5% health volunteer is less than 1.4 (that is, false positive rate is 10.5%); With reference to Fig. 2, can clearly be seen that (namely blood sample MD (Fl) index of 97.0% leukaemic is less than 5.2, accuracy rate of diagnosis is 97.0%), only blood sample MD (Fl) index of % health volunteer is greater than 5.2 (that is, false positive rate is 5.3%).Therefore, the diagnostic mode of this fact Example is adopted easily to be made a distinction by the blood sample of normal subjects and leukaemic.
Embodiment 2
The step whole blood DNA to above 52 experimenters identical with embodiment 1 is adopted to detect, difference is, use pH is the PBS damping fluid of 6.5,8 minutes then rapid quenchings at 10 DEG C are heated at 85 DEG C, the prepared absorbance of 52 parts of solution C at 260nm place is 0.1-0.3, use compound to be:
The concentration of compound is 10uM.
Testing result: the Detection accuracy adopting MD (A) index is 93.94%, and false positive rate is 10.52%; The Detection accuracy adopting MD (Fl) index is 90.91%, and false positive rate is 0%.
Embodiment 3
The step whole blood DNA to above 52 experimenters identical with embodiment 1 is adopted to detect, difference is, use pH is the PBS damping fluid of 7.0,5 minutes then rapid quenchings at 5 DEG C are heated at 90 DEG C, the prepared absorbance of 52 parts of solution C at 260nm place is 0.2-0.7, use compound to be
The concentration of compound is 20uM.
Testing result: the Detection accuracy adopting MD (A) index is 96.97%, and false positive rate is 5.26%; The Detection accuracy adopting MD (Fl) index is 93.94%, and false positive rate is 5.26%.
Embodiment 4
The step whole blood DNA to above 52 experimenters identical with embodiment 1 is adopted to detect, difference is, use the PBS damping fluid that pH is, 4 minutes then rapid quenchings at 10 DEG C are heated at 95 DEG C, the prepared absorbance of 52 parts of solution C at 260nm place is 0.5-0.9, use compound to be
The concentration of compound is 40uM.
Testing result: the Detection accuracy adopting MD (A) index is 87.88%, and false positive rate is 15.79%; The Detection accuracy adopting MD (Fl) index is 93.94%, and false positive rate is 15.79%.
Embodiment 5
The step whole blood DNA to above 52 experimenters identical with embodiment 1 is adopted to detect, difference is, use the PBS damping fluid that pH is, 4 minutes then rapid quenchings at 5 DEG C are heated at 95 DEG C, the prepared absorbance of 52 parts of solution C at 260nm place is 0.05-0.4, use compound to be
The concentration of compound is 50uM.
Testing result: the Detection accuracy adopting MD (A) index is 90.91%, and false positive rate is 10.52%; The Detection accuracy adopting MD (Fl) index is 96.97%, and false positive rate is 5.26%.
Embodiment 6
The step whole blood DNA to above 52 experimenters identical with embodiment 1 is adopted to detect, difference is, use the PBS damping fluid that pH is, 5 minutes then rapid quenchings at 4 DEG C are heated at 90 DEG C, the prepared absorbance of 52 parts of solution C at 260nm place is 0.2-0.5, use compound to be
The concentration of compound is 70uM.
Testing result: the Detection accuracy adopting MD (A) index is 93.94%, and false positive rate is 5.26%; The Detection accuracy adopting MD (Fl) index is 96.97%, and false positive rate is 0%.
Embodiment 7
The step whole blood DNA to above 52 experimenters identical with embodiment 1 is adopted to detect, difference is, use the PBS damping fluid that pH is, 5 minutes then rapid quenchings at 4 DEG C are heated at 90 DEG C, the prepared absorbance of 52 parts of solution C at 260nm place is 0.1-0.3, use compound to be
The concentration of compound is 100uM.
Testing result: the Detection accuracy adopting MD (A) index is 90.91%, and false positive rate is 15.79%; The Detection accuracy adopting MD (Fl) index is 90.91%, and false positive rate is 10.52%.
Comparative example
Adopt the step whole blood DNA to above 52 experimenters identical with embodiment 1 to detect, difference is, uses compound
solution preparation solution C, the concentration of this compound in solution C is 50uM.
Testing result: the Detection accuracy adopting MD (A) index is 60.61%, and false positive rate is 63.16%; The Detection accuracy adopting MD (Fl) index is 69.70%, and false positive rate is 36.84%.
As can be seen here, when using this compound, the blood sample of health volunteer and leukaemic can not be distinguished.
Although describe in detail the present invention in the mode of specific embodiment, but be apparent that to those skilled in the art, when not departing from the spirit and scope of the present invention that appended claims limits, can carry out variations and modifications to the present invention, these changes and amendment comprise within the scope of the invention equally.
Claims (8)
1., for diagnosing a leukemic kit by peripheral blood, comprise reagent I and reagent II, wherein said reagent I to be pH value be 6 ~ 8 damping fluid, described reagent II is the compound of formula I:
Wherein: R
1for C
1-C
6alkyl, phenyl, alkyl replace phenyl; R
2and R
3independently selected from H or C
1-C
6alkyl, or R
2and R
3the ring structure of 5 yuan to 7 yuan is formed together with the carbon atom that they connect; R
4and R
5independently selected from H or C
1-C
6alkyl, or R
4and R
5the ring structure of 5 yuan to 7 yuan is formed together with the carbon atom that they connect; R
6and R
7independently selected from C
1-C
6alkyl; Y is halogen; X
1, X
2independently be selected from C, O, S, Se, Te.
2. kit as claimed in claim 1, wherein said damping fluid is the damping fluid containing monovalent metallic ion.
3. kit as claimed in claim 1 or 2, described damping fluid is selected from sodium phosphate-phosphoric acid hydrogen sodium damping fluid, potassium phosphate-potassium hydrogen phosphate damping fluid, barbital sodium-hydrochloride buffer or citric acid-sodium citrate damping fluid.
4. kit, wherein R as claimed in claim 1
1be selected from methyl, ethyl, n-pro-pyl, isopropyl, normal-butyl, isobutyl, the tert-butyl group, amyl group, isopentyl, n-hexyl, isohesyl, phenyl, aminomethyl phenyl or 3,5-dimethylphenyl.
5. kit, wherein R as claimed in claim 1
2, R
3, R
4and R
5independently selected from methyl, ethyl, n-pro-pyl, isopropyl, normal-butyl, isobutyl, the tert-butyl group, amyl group, isopentyl, n-hexyl or isohesyl.
6. kit as claimed in claim 1, wherein at R
2and R
3when the carbon atom be connected with them forms ring structure, described ring structure is saturated rings or unsaturated ring, contains or does not contain N or S atom.
7. kit as claimed in claim 1, wherein at R
4and R
5when the carbon atom be connected with them forms ring structure, described ring structure is saturated rings or unsaturated ring, contains or does not contain N or S atom.
8. kit as claimed in claim 1, wherein Y is fluorine, chlorine, bromine or iodine.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210041112.2A CN102608051B (en) | 2012-02-21 | 2012-02-21 | Reagent kit for diagnosis of leukemia |
| PCT/CN2013/071728 WO2013123882A1 (en) | 2012-02-21 | 2013-02-21 | Method, kit and system for diagnosis of leukemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210041112.2A CN102608051B (en) | 2012-02-21 | 2012-02-21 | Reagent kit for diagnosis of leukemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102608051A CN102608051A (en) | 2012-07-25 |
| CN102608051B true CN102608051B (en) | 2015-04-08 |
Family
ID=46525606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210041112.2A Active CN102608051B (en) | 2012-02-21 | 2012-02-21 | Reagent kit for diagnosis of leukemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102608051B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013123882A1 (en) * | 2012-02-21 | 2013-08-29 | 中国科学院化学研究所 | Method, kit and system for diagnosis of leukemia |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101024730A (en) * | 2006-02-23 | 2007-08-29 | 中国科学院化学研究所 | Method for conducting chiral induction to non-chiral cyanine dye aggregate using human serum protein |
| CN101128218A (en) * | 2005-01-07 | 2008-02-20 | 拜耳先灵医药股份有限公司 | Use of cyanine dyes for the diagnosis of proliferative diseases |
| US20090148384A1 (en) * | 2007-12-10 | 2009-06-11 | Fischer Katrin | Functionalized, solid polymer nanoparticles comprising epothilones |
| CN101587070A (en) * | 2008-05-23 | 2009-11-25 | 中国科学院化学研究所 | The application of supramolecular ordered body in detecting G-four serobila structural DNAs |
| CN101587066A (en) * | 2008-05-23 | 2009-11-25 | 中国科学院化学研究所 | The new purposes of cyanine dyes in detecting G-four serobila structural DNAs |
| CN101946171A (en) * | 2007-12-14 | 2011-01-12 | 拜奥蒂乌姆股份有限公司 | Fluorescent compounds |
| WO2011118579A1 (en) * | 2010-03-25 | 2011-09-29 | 国立大学法人富山大学 | Fluorescent probe for plasma cell identification and isolation, and plasma cell identification or isolation method using the probe |
| WO2011151287A1 (en) * | 2010-05-31 | 2011-12-08 | Ludwig-Maximilians-Universität München | Naphthocyanines for use as contrast agents |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5268486A (en) * | 1986-04-18 | 1993-12-07 | Carnegie-Mellon Unversity | Method for labeling and detecting materials employing arylsulfonate cyanine dyes |
| ATE522580T1 (en) * | 2003-10-31 | 2011-09-15 | Ge Healthcare Ltd | CYANINE DYES AS MARKING AGENTS |
| CN101231243B (en) * | 2007-01-24 | 2011-11-16 | 深圳迈瑞生物医疗电子股份有限公司 | Agent and method for testing reticulocyte |
| CN101750476B (en) * | 2008-12-08 | 2015-06-03 | 深圳迈瑞生物医疗电子股份有限公司 | Blood analysis reagent and use method thereof |
| CN101750274B (en) * | 2008-12-17 | 2014-06-25 | 深圳迈瑞生物医疗电子股份有限公司 | Differential blood count reagent, kit and method of differential blood count |
-
2012
- 2012-02-21 CN CN201210041112.2A patent/CN102608051B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101128218A (en) * | 2005-01-07 | 2008-02-20 | 拜耳先灵医药股份有限公司 | Use of cyanine dyes for the diagnosis of proliferative diseases |
| CN101024730A (en) * | 2006-02-23 | 2007-08-29 | 中国科学院化学研究所 | Method for conducting chiral induction to non-chiral cyanine dye aggregate using human serum protein |
| US20090148384A1 (en) * | 2007-12-10 | 2009-06-11 | Fischer Katrin | Functionalized, solid polymer nanoparticles comprising epothilones |
| CN101946171A (en) * | 2007-12-14 | 2011-01-12 | 拜奥蒂乌姆股份有限公司 | Fluorescent compounds |
| CN101587070A (en) * | 2008-05-23 | 2009-11-25 | 中国科学院化学研究所 | The application of supramolecular ordered body in detecting G-four serobila structural DNAs |
| CN101587066A (en) * | 2008-05-23 | 2009-11-25 | 中国科学院化学研究所 | The new purposes of cyanine dyes in detecting G-four serobila structural DNAs |
| WO2011118579A1 (en) * | 2010-03-25 | 2011-09-29 | 国立大学法人富山大学 | Fluorescent probe for plasma cell identification and isolation, and plasma cell identification or isolation method using the probe |
| WO2011151287A1 (en) * | 2010-05-31 | 2011-12-08 | Ludwig-Maximilians-Universität München | Naphthocyanines for use as contrast agents |
Non-Patent Citations (6)
| Title |
|---|
| A comparative study of the photosensitizing characteristics of some cyanine dyes;E. Delaey，et al.;《J. Photochem. Photobiol. B: Biol.》;20000330;第55卷(第1期);27-36 * |
| Amaresh Mishra,et al..Cyanines during the 1990s: A Review.《Chem. Rev.》.2000,第1992页左栏第21行至左栏结尾,右栏第2段1-9行和第3段,第2006页左栏第1段,全文化学式结构. * |
| G-Quadrup lex-specific peptide-hemicyanine ligands by partical combinatorial selection;james A.ET AL;《American Chemical society》;20030417;第125卷;5594-5595 * |
| Spectroscopic recognition of guanine dimeric hairpin quadruplexes by a carbocyanine dye;QI CHEN ET AL.;《Pro.Natl.Acad.Sci.USA》;19960430;第93卷;2635-2639 * |
| Verification of specific G-quadruplex structure by;Qianfan Yang，et al.;《Nucleic Acids Research》;20091119;第38卷(第3期);1022–1033 * |
| 安秋荣,等.卤碳菁增感染料的FABMS研究.《河北大学学报(自然科学版)》.1995,第15卷(第1期),第78页摘要摘要,第79页第2段. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102608051A (en) | 2012-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tang et al. | CEA in breast ductal secretions as a promising biomarker for the diagnosis of breast cancer: a systematic review and meta-analysis | |
| CN104897907B (en) | A kind of test kit detecting glycolated hemoglobin and detection method thereof | |
| CN106083888B (en) | The fluorescence probe of hydrogen sulfide in a kind of detection cancer cell | |
| CN108398361B (en) | Method for predicting blood disease outcome by using erythrocyte DNA damage signal and application thereof | |
| CN108982447A (en) | It is a kind of for detecting the preparation method and application of the ratio formula fluorescence probe of hydrazine | |
| Dawuti et al. | Urine surface-enhanced Raman spectroscopy combined with SVM algorithm for rapid diagnosis of liver cirrhosis and hepatocellular carcinoma | |
| CN107356757B (en) | A kind of oral squamous cell carcinomas early diagnosis reagent, kit, detection method and application | |
| CN101344526A (en) | Fast and accurate prostatic cancer detection test paper strip and its preparation and application | |
| CN102703569B (en) | New use of cyanine dyes | |
| CN109253998A (en) | Metal-wrappage-antibody composite nanoparticle quantitative detection tumor marker method based on Raman enhancing | |
| Ye et al. | Unexpected dual-functional cyanine fluorophores: NIR multifunctional fluorescent probes for simultaneous monitoring of mitochondrial cysteine/viscosity during kidney ferroptosis in vivo | |
| CN102608051B (en) | Reagent kit for diagnosis of leukemia | |
| CN102608052B (en) | System for diagnosis of leukemia | |
| CN102706842B (en) | Kit and system for diagnosing leukemia | |
| CN102749453B (en) | Applications of retinoic acid induced protein 16 (RAI16) as hepatocellular carcinoma marker | |
| CN203530312U (en) | Detection diagnosis device for tumor cells or other pathological cells | |
| CN102706787B (en) | New application of cyanine dye | |
| CN103361265B (en) | Cancer cell or other pathologic cell detection diagnostic device | |
| CN102841201B (en) | Combined general check protein chip for early-stage cancers mainly comprising lung cancer | |
| CN108572251A (en) | Hepatic sclerosis early stage small molecule marker and its application | |
| CN102175674A (en) | Method for detecting trace of albumin in urine | |
| CN102706788B (en) | System for detecting breast cancer | |
| Devanesan et al. | Fluorescence spectroscopy as a novel technique for premarital screening of sickle cell disorders | |
| CN102735831B (en) | Uses of truncated retinoic acid induced protein 16 (tRAI16) as hepatocellular carcinoma marker | |
| CN108893534A (en) | General cancer diagnosis marker |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |